RNXT

RenovoRx, Inc.

1.35 USD
+0.14 (+11.57%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

RenovoRx, Inc. stock is up 11.57% since 30 days ago. The next earnings date is Aug 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 May’s closed higher than April.

About RenovoRx, Inc.

RenovoRx, Inc. focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath.